A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
In early medieval Europe, some accounts stated that Common Vervain was used to staunch Jesus' wounds after his removal from the cross; hence names like "Holy Herb" or (e.g. in Wales) "Devil's bane". Because of the association with the Passion of Christ, it came to be used in ointments to drive out and repel "demonic" illnesses. Vervain flowers are engraved on cimaruta, Italian anti-stregheria charms. In the 1870 The History and Practice of Magic by "Paul Christian" (Jean-Baptiste Pitois) it is employed in the preparation of a mandragora charm. A Royal Navy Arabis-class sloop of the World War I era was named HMS Verbena, and in World War II a Group 1 Flower-class corvette bore the same name; a Group 2 vessel of the latter class was called HMS Vervain. The only Verbena widely found in England in a wild state is common vervain, though it is just as possible that the names reference the popular ornamental verbenas, such as the garden vervain.
cellular immunity Also cell-mediated immunity. A class of immune response that does not rely on the production of antibodies but rather the activation of specific cell types such as phagocytes or cytotoxic T-lymphocytes, or the secretion of various cytokines from cells, in response to an antigen.
Since AlphaFold outputs protein coordinates directly, AlphaFold produces predictions in graphics processing unit (GPU) minutes to GPU hours, depending on the length of protein sequence. The European Bioinformatics Institute together with DeepMind have constructed the AlphaFold – EBI database for predicted protein structures.
Sources: en.wikipedia.org
Thus, while in vitro receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects. DMT produces the head-twitch response (HTR), a behavioral proxy of psychedelic-like effects, in rodents. However, its effects in the HTR paradigm in mice that are highly strain-dependent, including producing an HTR comparable to other psychedelics, producing an HTR that is much weaker than that of other psychedelics, or producing no HTR at all. These conflicting results may be due to rapid metabolism of DMT and/or other peculiarities of DMT in different species. Besides the HTR, DMT also substitutes for LSD and DOM in rodent drug discrimination tests. DMT has been found to increase oxytocin levels in humans. It is thought that the rate at which DMT enters the brain, and hence its route of administration, may influence its effects, with more rapid routes like intravenous administration and inhalation potentiating serotonin 5-HT2A receptor activation and consequent hallucinogenic effects. As an example, a bolus intravenous injection of 15 mg DMT produces stronger peak effects than a continuous infusion of 1 mg/minute given over 1.5 hours in spite of the latter achieving higher peak DMT levels.
Various other experiments have shown that, besides bearing polymerase properties, ribozymes could have developed other kinds of evolutionarily useful catalytic activity such as synthase, ligase, or aminoacylase activities. Ribozymal aminoacylators and ribozymes with the ability to form peptide bonds might have been crucial to inventing translation. An RNA ligase, in turn, could link various components of quasispecies into one chain, beginning the process of a genome integration. An RNA with a synthase or a synthetase activity could be critical for building compartments and providing building blocks for growing RNA and protein chains as well as other types of molecules. Many examples of this kind of ribozyme are currently known, including a peptidyl transferase ribozyme, a ligase, and a nucleotide synthetase. A transaminoacylator described in 2013 has five nucleotides, which is sufficient for a trans-amino acylation reaction and makes it the smallest ribozyme that has been discovered. It supports a peptidyl-RNA synthesis that could be a precursor for the contemporary process of linking amino acids to tRNA molecules. An RNA ligase's catalytic domain, consisting of 93 nucleotides, proved to be sufficient to catalyse a linking reaction between two RNA chains. Similarly, an acyltransferase ribozyme 82 nucleotides long was sufficient to perform an acyltransfer reaction. Altogether, the results concerning the RNA ligase's catalytic domain and the acyltransferase ribozyme are in agreement with the estimated upper limit of 100 nucleotides set by the error threshold problem.
== Performance and comparison to other aerosol detectors == The CAD and evaporative light scattering detector (ELSD) are mass-flow sensitive detectors (response is proportional to mass of analyte reaching the detector per unit time) as opposed to concentration sensitive (response is proportional to analyte concentration within the eluent at a particular time) detectors such as UV detectors. Both the CAD and ELSD exhibit non-linear responses for most sample types; however, over small ranges (e.g. 1–100 ng) CAD response is reasonably linear. The shape of the response curves are different between the two detectors. Both detectors require the use of fully volatile mobile phases and non-volatile samples. CAD response is dependent on organic content of the mobile phase, response is higher with organic-rich mobile phases than aqueous ones. CAD response is quite uniform for non-volatile analytes with detection limit 1–3 ng; however, the response for ionised basic analytes can be larger than for neutral analytes. When properly individually optimized, both the CAD and ELSD show similar responses. Failure to regularly clean and optimize the mobile phase and gas flow properties of the detector leads to intra- and inter-day precision/ reproducibility errors.
Sources: en.wikipedia.org
The Blood resource focus on the individual protein levels in blood of both healthy individuals and patients diagnosed with various diseases. Here you can explore: - The individual protein levels in blood from healthy individuals and patients diagnosed with diseases. - The longitudinal blood protein levels in healthy individuals during two years. - The longitudinal blood protein levels in children through puberty. - The effect of age, BMI and sex on the individual protein levels in blood. - The levels of plasma proteins using immune assays and mass spectrometry. The Subcellular resource of the Human Protein Atlas provides high-resolution insights into the expression and spatiotemporal distribution of proteins encoded by 13603 genes (67% of the human protein-coding genes) as well as predictions for an additional 3459 secreted- or membrane proteins, covering a total of 17062 genes (85% of the human protein-coding genes). For each gene, the subcellular distribution of the protein has been investigated by immunofluorescence (ICC-IF) and confocal microscopy in up to three different cell lines, selected from a panel of 42 cell lines used in the subcellular resource. Upon image analysis, the subcellular localization of the protein has been classified into one or more of 35 different organelles and fine subcellular structures. For some genes, the protein has also been stained in up to three ciliated cell lines, induced pluripotent stem cells (iPSCs) and/or in human sperm cells.
analytical chemistry The branch of chemistry which studies and makes use of instruments and methods to separate, quantify, and identify chemical substances, both by classical wet chemistry techniques such as precipitation, extraction, distillation, and observational analysis, and by modern instrumental techniques such as chromatography, spectroscopy, and electrochemistry.
Navy Warrant Officer Class 1 D Lennon Chief Petty Officer M Rodway Army Warrant Officer Class 1 Matthew James Anderson, Royal Corps of Signals Warrant Officer Class 1 Rupert St John Hardington Banfield, , Army Air Corps Warrant Officer Class 1 Peter Bernthal, Corps of Royal Electrical and Mechanical Engineers Staff Sergeant Troy David Binding Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Aarron David Butterworth, Corps of Royal Engineers Warrant Officer Class 1 (now Captain) Adam Daniel Cooksey, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Leslie Trevor Dinsmore, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Darren Lee Duckitt, The Royal Yorkshire Regiment Warrant Officer Class 2 Kulbahadur Ghale, The Royal Gurkha Rifles Warrant Officer Class 1 (now Captain) Marc Kevin Giles, , The Mercian Regiment Warrant Officer Class 1 Philip John Greenway, Royal Regiment of Artillery Warrant Officer Class 1 Adam Charles Ireland, The Parachute Regiment Warrant Officer Class 1 Manojkumar Jugjali, The Royal Gurkha Rifles Warrant Officer Class 1 Carley Lorraine Lambert, Royal Regiment of Artillery Warrant Officer Class 1 James Lee Lightfoot, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Daniel Andrew Long, The Rifles Warrant Officer Class 1 James Derek Mayoh, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Stuart Russell McCreadie, Royal Corps of Signals Warrant Officer Class 1 Peter Steven Meager, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 (now Captain) Ryan Daniel O'Neill, The Royal Regiment of Scotland Warrant Officer Class 1 James Edward Phillips, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Michael John Potts, Royal Army Medical Corps Warrant Officer Class 2 Prakash Rai, Royal Army Medical Corps Warrant Officer Class 2 Kyle Reains, Irish Guards Warrant Officer Class 1 James Wright Reid, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 James Oliver Richardson, Royal Regiment of Artillery Warrant Officer Class 1 Aran Christopher Rushe, Royal Army Medical Corps Warrant Officer Class 1 Grant Spencer Sewell-Jones, Royal Corps of Army Music Warrant Officer Class 1 Paul Sheenan, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Melanie Louise Silvester, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Garry Andrew Smurthwaite, The Parachute Regiment Warrant Officer Class 2 David Robert John Steel, The Royal Scots Dragoon Guards Warrant Officer Class 1 John Ian Sweeney, Army Air Corps Warrant Officer Class 2 (now Captain) Trevor Albert Tuhey, Royal Army Physical Training Corps Warrant Officer Class 1 Russell James Underwood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 George Ferguson Francis Wong Vesi, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Jonathan George Werrett, The Mercian Regiment Warrant Officer Class 1 Joseph Thomas Williams, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Michael James Williams, Royal Corps of Signals Warrant Officer Class 1 David Wood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Craig Michael Woodall, Royal Army Veterinary Corps Warrant Officer Class 2 Robert Steven Young, Welsh Guards Air Force Warrant Officer (now Flight Lieutenant) J. Blinkhorn Warrant Officer (now Flight Lieutenant) H. Dimeck Warrant Officer (now Flight Lieutenant) F.E. Hunt Warrant Officer D.P. Burke Warrant Officer W.O.R Clements Warrant Officer N.W. Cook Master Aircrew A.R. Davey, Warrant Officer J.C. Foxall Warrant Officer D.G. Jackson Warrant Officer K.E. Jones Warrant Officer E.L. Kerslake Warrant Officer M.E. Larkin Warrant Officer D.A. Lawrence Warrant Officer R. Laycock Warrant Officer B. Moore Warrant Officer C.L.S Old Master Aircrew S.R. Parsons Warrant Officer K.N. Phillips Warrant Officer S.G. Rowbotham Warrant Officer A. Wilson Warrant Officer P.B. Wilson, Warrant Officer S.M. Wooles Acting Warrant Officer K.S. Edwards Acting Warrant Officer A.S. MacDonald Flight Sergeant M.J. Moore Flight Sergeant J.C. O'Grady Flight Sergeant J.A. Simpkins Flight Sergeant C.A. Smith Flight Sergeant P.S. Ware Flight Sergeant L.A. Williams Chief Technician D.G. Bristow Sergeant E.P. Jones
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.